Use the statistic functions workspace to apply Beta function and other studies to Catalyst Pharmaceuticals. The focus on statistical functions describing dispersion and variability helps organize trend, volatility, and risk context for Catalyst Pharmaceuticals.Enter Time Period to start the analysis.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Catalyst Pharmaceuticals correlated with the market. If Beta is less than 0 Catalyst Pharmaceuticals generally moves in the opposite direction as compared to the market. If Catalyst Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Catalyst Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Catalyst Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Catalyst Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Most technical analysis of Catalyst Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Catalyst from various momentum indicators to cycle indicators. When you analyze Catalyst charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Catalyst Pharmaceuticals is scheduled to announce its earnings this week.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. As a large-cap equity, Catalyst Pharmaceuticals is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 23.62, P/B of 3.12, profit margin of 36.39%. Catalyst Pharmaceuticals has a market cap of 3 B, P/E of 23.62, ROE of 25.49%.
Methodology
Unless otherwise specified, financial data for Catalyst Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Catalyst (USA Stocks:CPRX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Catalyst Pharmaceuticals is covered by 7 analysts. 3 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, Raymond James, Bernstein Research, among others. Updates may occur throughout the day.
Tracking Catalyst Pharmaceuticals inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
Reviewing Catalyst Pharmaceuticals commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Catalyst Stock:
Catalyst Pharmaceuticals has a market cap of 3 B, operating margin of 40.53%, ROE of 25.49%. See Trending Equities for portfolio-level analysis. This suggests a position in Catalyst Pharmaceuticals within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Our How to Buy Catalyst Stock guide explains the steps to invest in Catalyst Pharmaceuticals stock.Analysis related to Catalyst Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Quarterly Earnings Growth
-0.06
Earnings Share
1.68
Revenue Per Share
4.816
Quarterly Revenue Growth
0.076
Return On Assets
0.1648
Understanding Catalyst Pharmaceuticals includes distinguishing between market value and book value, where book value reflects Catalyst accounting equity. Catalyst Pharmaceuticals' market capitalization is 3 B. With a P/B ratio of 3.12, the market values Catalyst Pharmaceuticals well above its book equity. Enterprise value stands at 2.27 B. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
The concept of value for Catalyst Pharmaceuticals differs from its quoted price, since each reflects a different lens. For Catalyst Pharmaceuticals, key inputs include a P/E ratio of 23.62, a P/B ratio of 3.12, a profit margin of 36.39%, and ROE of 25.49%. Trading price represents the transaction level agreed by market participants.
Gabriel Shpitalnik ยท Member of Macroaxis Editorial Board